BPR1K871

BPR1K871 is a potent and selective dual FLT3/AURKA inhibitor with IC50s of 19 nM and 22 nM for FLT3 and AURKA, respectively, acts as a preclinical development candidate for anti-cancer therapy.

Product information

CAS Number: 2443767-35-7

Molecular Weight: 526.05

Formula: C25H28ClN7O2S

Chemical Name: 1-(3-chlorophenyl)-3-{5-[2-({7-[3-(dimethylamino)propoxy]quinazolin-4-yl}amino)ethyl]-1,3-thiazol-2-yl}urea

Smiles: CN(C)CCCOC1=CC2=NC=NC(NCCC3=CN=C(NC(=O)NC4=CC(Cl)=CC=C4)S3)=C2C=C1

InChiKey: MMVLETOTGHDVPQ-UHFFFAOYSA-N

InChi: InChI=1S/C25H28ClN7O2S/c1-33(2)11-4-12-35-19-7-8-21-22(14-19)29-16-30-23(21)27-10-9-20-15-28-25(36-20)32-24(34)31-18-6-3-5-17(26)13-18/h3,5-8,13-16H,4,9-12H2,1-2H3,(H,27,29,30)(H2,28,31,32,34)

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : 125 mg/mL (237.62 mM; Need ultrasonic).

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

BPR1K871 shows potent anti-proliferative activities in MOLM-13 and MV4-11 AML cells with an EC50 of ~ 5 nM.

In Vivo:

BPR1K871 is a multi-kinase inhibitor for the treatment of acute myeloid leukemia (AML) and solid tumors.

Products are for research use only. Not for human use.